Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore professional investment ideas sourced from institutional letters, short theses, and premium research channels, distilled into concise summaries.
| Pitch Type | Author | Industry | Pitch Thesis & Key Summary | Bull/Bear | Action | ||
|---|---|---|---|---|---|---|---|
| Sep 2, 2026 | Fund Letter | John G. KhabbazPhoenician Capital | Halozyme Therapeutics $HALO• NASDAQ | BiotechnologyBiotechnology | Phoenician Capital - HALO HALO licenses a technology, ENHANZE®, that allows large pharmaceutical companies to replace hours on an IV drip for a quick shot under the skin. The technology works... | NEUTRAL | View Pitch → |
| Jan 8, 2026 | Fund Letter | ArrowMark Colorado Holdings, LLCMeridian Growth Fund | Halozyme Therapeutics $HALO• NASDAQ | BiotechnologyBiotechnology | Meridian Growth Fund 2025 Q2 (HALO) Halozyme Therapeutics, Inc. is a leading drug delivery platform company built around its proprietary and commercially validated ENHANZE® technology. This innovative enzyme... | BULL | View Pitch → |
| Nov 28, 2025 | Fund Letter | ArrowMark Colorado Holdings, LLCMeridian Growth Fund | Halozyme Therapeutics $HALO• NASDAQ | BiotechnologyBiotechnology | Meridian Growth Fund 2025 Q3 (HALO) Halozyme Therapeutics, Inc. is a leading drug delivery platform company built around its proprietary and commercially validated ENHANZE® technology. This innovative enzyme... | BULL | View Pitch → |
Join institutional and professional investors receiving our weekly analysis of hedge fund letters, market trends, and high-conviction ideas.
Zero Spam • High Alpha • Unsubscribe Anytime
Investment pitches and theses displayed on Buyside Digest are summaries of opinions expressed in publicly available investor letters, research reports, or other commentary. These summaries are generated for informational and research purposes only and do not constitute investment recommendations, financial advice, or an endorsement of any particular security or strategy by Buyside Digest. Users should conduct their own independent due diligence and consult with professional advisors before making any investment decisions.